Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.44 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 15/20 | 0.42 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10162211 | 0.95 | MMP13 (0.43) | MMP13ADAMTS4MMP3MAPK1RPS6KA1 | |
| SCHEMBL8253371 | 0.93 | MMP13 (0.45) | MMP13ADAMTS4MMP3MAPK1RPS6KA1 | |
| SCHEMBL10162218 | 0.93 | MMP13 (0.46) | MMP13ADAMTS4MMP3MAPK1RPS6KA1 | |
| SCHEMBL8246532 | 0.92 | MMP13 (0.45) | MMP13ADAMTS4MMP3MAPK1RPS6KA1 | |
| SCHEMBL10162167 | 0.92 | MMP13 (0.45) | MMP13ADAMTS4MMP3MAPK1RPS6KA1 | |
| SCHEMBL10162205 | 0.91 | MMP13 (0.46) | MMP13ADAMTS4MMP3MAPK1RPS6KA1 | |
| SCHEMBL8256766 | 0.91 | MMP13 (0.44) | MMP13ADAMTS4MMP3MAPK1RPS6KA1 | |
| SCHEMBL10165621 | 0.91 | MMP13 (0.44) | MMP13ADAMTS4MMP3MAPK1RPS6KA1 | |
| SCHEMBL8247135 | 0.91 | MMP13 (0.46) | MMP13ADAMTS4MMP3MAPK1RPS6KA1 | |
| SCHEMBL10165481 | 0.90 | MMP13 (0.45) | MMP13ADAMTS4MMP3MAPK1RPS6KA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885 |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.